The role of the immune system in osteoarthritis: mechanisms, challenges and future directions
- PMID: 40082724
- DOI: 10.1038/s41584-025-01223-y
The role of the immune system in osteoarthritis: mechanisms, challenges and future directions
Abstract
Osteoarthritis (OA) is a chronic joint disease that has long been considered a simple wear-and-tear condition. Over the past decade, research has revealed that various inflammatory features of OA, such as low-grade peripheral inflammation and synovitis, contribute substantially to the pathophysiology of the disease. Technological advances in the past 5 years have revealed a large diversity of innate and adaptive immune cells in the joints, particularly in the synovium and infrapatellar fat pad. Notably, the presence of synovial lymphoid structures, circulating autoantibodies and alterations in memory T cell and B cell populations have been documented in OA. These data indicate a potential contribution of self-reactivity to the disease pathogenesis, blurring the often narrow and inaccurate line between chronic inflammatory and autoimmune diseases. The diverse immune changes associated with OA pathogenesis can vary across disease phenotypes, and a better characterization of their underlying molecular endotypes will be key to stratifying patients, designing novel therapeutic approaches and ultimately ameliorating treatment allocation. Furthermore, examining both articular and systemic alterations, including changes in the gut-joint axis and microbial dysbiosis, could open up novel avenues for OA management.
© 2025. Springer Nature Limited.
Conflict of interest statement
Competing interests: F.B. received an institutional grant from TRB Chemedica and Pfizer and consulting fees from AstraZeneca, Boehringer Ingelheim, Bone Therapeutics, Cellprothera, Galapagos, Gilead, Grunenthal, GSK, Lilly, MerckSerono, MSD, Nordic Bioscience, Novartis, Pfizer, Roche, Sandoz, Sanofi, Servier, UCB, Peptinov, 4 P Pharma and 4Moving Biotech. J.S. reports personal fees from MSD, Pfizer, AbbVie, Fresenius Kabi, BMS, Lilly, Novartis, Galapagos, AstraZeneca, UCB, Grunenthal and Janssen and research grants from Pfizer and Schwa Medico. J.G. received consulting fees from BMS, Graftys, PKmed, HTL biotechnology, Cellprothera, GSK, Peptinov and CEVA.
References
-
- Osteoarthritis Research Society International. Osteoarthritis: A Serious Disease, Submitted to the U.S. Food and Drug Administration White Paper (OARSI, 2016).
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous